Journal of Clinical Endocrinology & Metabolism, Vol 81, 1434-1441, Copyright © 1996 by Endocrine Society

ARTICLES

A two-site monoclonal antibody immunoradiometric assay for human follistatin: secretion by a human ovarian teratocarcinoma-derived cell line (PA-1)

QF Wang, RH Khoury, PC Smith, DS McConnell, V Padmanahban, AR Midgley Jr, AL Schneyer, WF Crowley Jr and PM Sluss
National Cooperative Pogram for Infertility Research, Massachusetts General Hospital, Boston, 02114, USA.

The follistatin/activin/inhibin system increasingly appears to have important growth and differentiating effects in a variety of cell types, including cancer. We have developed a two-site immunoradiometric assay for measurement of human follistatin using two monoclonal antibodies against recombinant human follistatin. This cloned protein donor assay is sensitive (0.5 ng/mL), specific for free human follistatin, and precise (<5% within assay coefficient of variation). Using this assay, native human follistatin could be measured in human pituitary extracts, follicular fluid, and granulosa-luteal cell- conditioned medium. To identify and characterize human follistatin secreted by ovarian cancer cells, we screened five human ovarian carcinoma cell lines currently available from the American Type Culture Collection (Rockville, MD). One of these, a cell line derived from a teratocarcinoma (designated PA-1, American Type Culture Collection, CRL1572), secreted large (3 microg/10(6) cells per 24 h) quantities of immunoreactive follistatin constituitively. Increasing volumes of conditioned medium from these cultured cells generated response curves parallel to those of recombinant human follistatin 288 reference protein, human follicular fluid, or culture medium from human granulosa- luteal cells. Secretion of follistatin by PA-1 cells was time and cell- number dependent with 297.9 +/- 15.2, 654 +/- 29.8, and 940 +/- 49.1 ng follistatin secreted over 24 h by 1 x 10(5), 2 x 10(5), and 3 x 10(5) cells, respectively. Western and ligand blot analysis revealed that the immunoreactive follistatin secreted by PA-1 cells and isolated by sulfate-cellufine chromatography was identical to the molecular weight variants (32,000 and 35,000 Mr) of recombinant human follistatin 288. PA-1 cell-conditioned medium suppressed basal secretion of FSH by cultured rat anterior pituitary cells in a dose-dependent fashion. This follistatin bioactivity was completely removed by adsorption with either solid-phase monoclonal antifollistatin or a dextran-sulfate chromatography gel. Because activin suppressed the proliferation of PA- 1 cells, secretion of bioactive follistatin may represent an autocrine mechanism opposing activin to maintain the rapid growth rate of PA-1 cells. These observations demonstrate that the ovarian teratocarcinoma cell line, PA-1, secretes considerable amounts of human follistatin that is biologically active, capable of binding human activin, and antigenically similar to recombinant human follistatin 288. The monoclonal antibodies and two-site assay reported herein should be useful in assessing the regulation of follistatin secretion and as a diagnostic tool, especially if follistatin measurements prove to be a marker for some ovarian cancers.

This article has been cited by other articles:

				K Rae, K Hollebone, V Chetty, D Clausen, and J McFarlane Follistatin serum concentrations during full-term labour in women significant differences between spontaneous and induced labour Reproduction, November 1, 2007; 134(5): 705 - 711. [Abstract] [Full Text] [PDF]

				Y. Sidis, A. L. Schneyer, and H. T. Keutmann Heparin and Activin-Binding Determinants in Follistatin and FSTL3 Endocrinology, January 1, 2005; 146(1): 130 - 136. [Abstract] [Full Text] [PDF]

				A. L. Schneyer, Q. Wang, Y. Sidis, and P. M. Sluss Differential Distribution of Follistatin Isoforms: Application of a New FS315-Specific Immunoassay J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5067 - 5075. [Abstract] [Full Text] [PDF]

				R. Rios, S. Fernandez-Nocelos, I. Carneiro, V. M. Arce, and J. Devesa Differential Response to Exogenous and Endogenous Myostatin in Myoblasts Suggests that Myostatin Acts as an Autocrine Factor in Vivo Endocrinology, June 1, 2004; 145(6): 2795 - 2803. [Abstract] [Full Text] [PDF]

				H. T. Keutmann, A. L. Schneyer, and Y. Sidis The Role of Follistatin Domains in Follistatin Biological Action Mol. Endocrinol., January 1, 2004; 18(1): 228 - 240. [Abstract] [Full Text] [PDF]

				K.-C. Choi, S. K. Kang, C.-J. Tai, N. Auersperg, and P. C. K. Leung The Regulation of Apoptosis by Activin and Transforming Growth Factor-{beta} in Early Neoplastic and Tumorigenic Ovarian Surface Epithelium J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2125 - 2135. [Abstract] [Full Text]

				Q. Wang, H. T. Keutmann, A. L. Schneyer, and P. M. Sluss Analysis of Human Follistatin Structure: Identification of Two Discontinuous N-Terminal Sequences Coding for Activin A Binding and Structural Consequences of Activin Binding to Native Proteins Endocrinology, September 1, 2000; 141(9): 3183 - 3193. [Abstract] [Full Text] [PDF]

				A. Delbaere, Y. Sidis, and A. L. Schneyer Differential Response to Exogenous and Endogenous Activin in a Human Ovarian Teratocarcinoma-Derived Cell Line (PA-1): Regulation by Cell Surface Follistatin Endocrinology, June 1, 1999; 140(6): 2463 - 2470. [Abstract] [Full Text]

				D. S. McConnell, Q. Wang, P. M. Sluss, N. Bolf, R. H. Khoury, A. L. Schneyer, A. R. Midgley Jr., N. E. Reame, W. F. Crowley Jr., and V. Padmanabhan A Two-Site Chemiluminescent Assay for Activin-Free Follistatin Reveals That Most Follistatin Circulating in Men and Normal Cycling Women Is in an Activin-Bound State J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 851 - 858. [Abstract] [Full Text]

				C. K. Welt, G. Lambert-Messerlian, W. Zheng, W. F. Crowley Jr., and A. L. Schneyer Presence of Activin, Inhibin, and Follistatin in Epithelial Ovarian Carcinoma J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3720 - 3727. [Abstract] [Full Text] [PDF]

				V. Padmanabhan, K. McFadden, D. T. Mauger, F. J. Karsch, and A. R. Midgley Jr. Neuroendocrine Control of Follicle-Stimulating Hormone (FSH) Secretion. I. Direct Evidence for Separate Episodic and Basal Components of FSH Secretion Endocrinology, January 1, 1997; 138(1): 424 - 432. [Abstract] [Full Text] [PDF]

				Y. Sidis, A. L. Schneyer, P. M. Sluss, L. N. Johnson, and H. T. Keutmann Follistatin: Essential Role for the N-terminal Domain in Activin Binding and Neutralization J. Biol. Chem., May 18, 2001; 276(21): 17718 - 17726. [Abstract] [Full Text] [PDF]